Выбор редакции

Isis Pharmaceuticals initiates study, earns milestone payment

  • Isis Pharmaceuticals (ISIS) starts a Phase 1 study of ISIS-GSK3 in "a therapeutic area where there is a significant need for better therapies."
  • The investigational drug "is designed to inhibit the production of an undisclosed target." (PR)
  • The initiation of the study earns ISIS a $3M milestone payment from GlaxoSmithKline (GSK).
  • ISIS +2.8% premarket
Post your comment!